Abstract
Studies were conducted to evaluate whether the timing of administration of ICRF-187 [(+)-1,2-bis(3,5 dioxopiperazinyl-1-yl)propane] would influence the degree of cardioprotection provided by this agent against the development of doxorubicin-induced chronic cardiomyopathy. Beagle dogs (8.5–14 kg) received either doxorubicin alone (1.75 mg/kg, i. v.,n=8), doxorubicin (1.75 mg/kg) simultaneously with ICRF-187 (35 mg/kg, i. v.,n=8), or doxorubicin (1.75 mg/kg) followed 2 h later by ICRF-187 (35 mg/kg,n=8). Control animals received ICRF-187 (35 mg/kg,n=4) or saline (n=4). All animals received a course of seven treatments, each given 3 weeks apart, and were killed 3 weeks after the last treatment. Semiquantitative grading of histologic sections of myocardium showed that as compared with animals treated with doxorubicin alone, the incidence and the severity of the doxorubicin-induced myocardial lesions were reduced in the two groups of animals given doxorubicin plus ICRF-187. However, protection was significantly better in dogs receiving ICRF-187 and doxorubicin simultaneously than in those given ICRF-187 2 h after doxorubicin. These observations were interpreted as indicating that the timing of administration of ICRF-187 with respect to that of doxorubicin is an important factor in determining the degree of cardioprotection and that there is a “time window” in which ICRF-187 exerts optimal effects.
Similar content being viewed by others
References
Baldwin JR, Phillips BA, Overmyer SK, Hatfield NF, Narang PK (1992) Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. Cancer Chemother Pharmacol 30:433
Bertazzoli C, Bellini O, Magrini U, Tosana MG (1979) Quantitative experimental evaluation of Adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 63:1877
Bristow MR, Billingham ME, Mason JW, Daniels TR (1978) Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873
Doroshow JH, Burke TG, VanBalgooy J, Akman S, Verhoef V (1991) Cellular pharmacology of ICRF-187 (ADR-529) in adult rat heart myocytes (M). Proc Am Assoc Cancer Res 32:332
Filppi JA, Imondi AR, Wolgemuth RL (1987) Characterization of the cardioprotective effect of (S)(+)-4,4′-propylene-2,6-piperazinedione (ICRF-187) on anthracycline cardiotoxicity. In: Harker MP, Lazo JS, Tritton TR (eds) Organ directed toxicities of anticancer drugs. Martinus Nijhoff, Boston, p 225
Gianni L, Zweier JL, Levy A, Myers C (1985) Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. J Biol Chem 260:6820
Giuliani F, Casazza AM, DiMarco A, Savi G (1981) Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Cancer Treat Rep 65:267
Goodman J, Hochstein P (1977) Generation of free-radicals and lipid peroxidation by redox cycling of Adriamycin and daunomycin. Biochem Biophys Res Commun 77:797
Hasinoff B (1989) The interaction of the cardioprotective agent ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane]; its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of Adriamycin. Agents Actions 26:378
Herman EH, Ferrans VJ (1981) Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187). Cancer Res 41:3436
Herman EH, Ferrans VJ (1983) Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine. Lab Invest 49:69
Herman E, Ardalan B, Waravdekar V, Krop S (1979) Amelioration of daunorubicin (NSC 82 151) lethality and myocardial cellular alterations by pretreatment with ICRF-187 (NSC 169 780) in Syrian golden hamsters. Cancer Treat Rep 63:89
Herman EH, Ferrans VJ, Jordan W, Ardalan B (1981) Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits. Res Commun Chem Pathol Pharmacol 31:85
Herman EH, El-Hage AN, Ferrans VJ, Witiak DT (1983) Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 40:217
Herman EH, El-Hage AN, Ferrans VJ (1985) Comparison of the severity of the chronic cardiotoxicity produced by doxorubicin in normotensive and hypertensive rats. Toxicol Appl Pharmacol 78:202
Herman EH, Ferrans VJ, Myers CE, Van Vleet JF (1985) Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) andN-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res 45:276
Herman EH, El-Hage A, Ferrans VJ (1988) Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats. Toxicol Appl Pharmacol 92:42
Kruskal WH, Wallis WA (1952) Use of ranks in one criterion variance analysis. J Am Stat Assoc 47:583
Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 34:302
Lefrak EA, Pitha J, Rosenheim S, O'Bryan RM, Burgess MA, Gottlieb JA (1975) Adriamycin (NSC 123 127) cardiomyopathy. Cancer Chemother Rep 6:203
Legha SS, Wang YM, Mackay B, Ewer M, Hortobagy GN, Benjamin RS, Ali MK (1982) Clinical and pharmacologic investigation of the effects of α-tocopherol on Adriamycin cardiotoxicity. Ann NY Acad Sci 393:411
Llesuy SF, Milei J, Molina H, Boveris A, Milei S (1985) Comparison of lipid peroxidation and myocardial damage induced by Adriamycin and 4′-epi-Adriamycin in mice. Tumori 72:241
McPherson E, Archila R, Schein PS, Tew KD, Mhatre RM (1984) Preclinical pharmacokinetics, disposition and metabolism of ICRF-187. Proc Am Assoc Cancer Res 25:1436
Mhatre RM, Tew KD, Van Hennik MB, Waravdekar VS, Schein PS (1983) Absorption, distribution and pharmacokinetics of ICRF-187 in dogs. Proc Am Assoc Cancer Res 24:1147
Monti E, Piccinini F, Villani F, Favalli L (1986) Myocardial contractility and heart pharmacokinetics of Adriamycin following a single administration in the rat. Cancer Chemother Pharmacol 18:289
Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC (1977) Adriamycin, the role of lipid peroxidation. Science 19:165
Wampler GL, Speckhart VJ, Regelson W (1974) Phase I clinical study of Adriamycin-ICRF-159 combination and other ICRF-159 drug combinations. Proc Am Assoc Cancer Res 15:189
Wang G, Finch MD, Trevan D, Hellmann K (1981) Reduction of daunomycin toxicity by razoxane. Br J Cancer 3:871
Yesair DW, Schwartzbach E, Shuck D, Denine EP, Asbell MA (1972) Comparative pharmacokinetics of daunomycin and Adriamycin in several animal species. Cancer Res 32:1177
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herman, E.H., Ferrans, V.J. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother. Pharmacol. 32, 445–449 (1993). https://doi.org/10.1007/BF00685888
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685888